Willem Mulder is a professor of Precision Medicine at both Radboudumc / Radboud University and the TU/e Department of Biomedical Engineering. His research focuses on precision immunotherapy and innovative molecular imaging approaches.
He develops nanotechnology for immunotherapy against cancer, inflammation, infectious and cardiovascular diseases, as well as to manage organ transplantation. Through the exploration of biological, chemical, and experimental knowledge, Mulder and his teams interconnect nanotechnology, imaging, and immunology with the overarching goal of developing nanomedicine strategies for detrimental immune-mediated diseases.
My overarching goal is to institutionalize nanotechnologies for precision immunotherapy and immuno-imaging. In addition to making such precision medicine approaches available to patients, I strive to cultivate a unique research environment for the next generation of biomedical engineers.
Willem Mulder obtained an MSc in Chemistry from Utrecht University (the Netherlands) in 2001 and a PhD in Biomedical Engineering from Eindhoven University of Technology (TU/e, the Netherlands) in 2006. Thereafter, he was recruited to the Icahn School of Medicine at Mount Sinai (New York, USA) where he founded the Nanomedicine Laboratory.
After a 15-year tenure at Mount Sinai, he returned to the Netherlands at the beginning of 2021 to establish a unique multidisciplinary research group spanning both the Radboud University Medical Center and the Eindhoven University of Technology. Participating in and driving innovative science today, allows young scientists from diverse backgrounds to flourish and mature into the engineers, scientists, and medical doctors of tomorrow.
Willem Mulder is co-founder and CSO of Trained Therapeutix Discovery, a scale-up biotech company developing nanobiologic immunotherapeutics. He also is the initiator, co-founder, and CTO of BioTrip, an entrepreneurial engine that is focused on developing innovative immunotherapies.
Regulating trained immunity with nanomedicineNature Reviews. Materials (2022)
Diverse ultrastructural landscape of atherosclerotic endotheliumAtherosclerosis (2021)
Embracing nanomaterials' interactions with the innate immune systemWiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology (2021)
Imaging-guided nanomedicine developmentCurrent Opinion in Chemical Biology (2021)
Nanoengineering Apolipoprotein A1-Based ImmunotherapeuticsAdvanced Therapeutics (2021)
Current Educational Activities
- Professor of Radiology / Director Nanomedicine Program, Icahn School of Medicine at Mount Sinai